Nehal Moaz Mehrez, Dina Abdallah Ibrahim, Maha Esmail El-Zaafarany, Dina A El-Tantawy, Azza Abdel-Aziz
{"title":"Immunohistochemical Expression of PD-L1 and CTLA-4 in Triple Negative Breast Cancer and Their Prognostic Associations.","authors":"Nehal Moaz Mehrez, Dina Abdallah Ibrahim, Maha Esmail El-Zaafarany, Dina A El-Tantawy, Azza Abdel-Aziz","doi":"10.31557/APJCP.2025.26.1.319","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Programmed Death-Ligand 1 (PD-L1) and Cytotoxic T Lymphocyte -Associated Antigen-4 (CTLA-4) are presently considered as prognostic markers and therapeutic targets in numerous human malignancies. The goal of this study was to determine whether PD-L1 and CTLA-4 might be used to predict patients' survival in Triple Negative Breast Cancer (TNBC).</p><p><strong>Methods: </strong>This retrospective cohort study analyzed 100 primary TNBC cases that had surgical resection at the Oncology Center of Mansoura University (OCMU), Faculty of Medicine, Egypt. Clinicopathological data and survival outcomes were collected, and immunohistochemistry (IHC) was performed for PD-L1 and CTLA-4 expression.</p><p><strong>Result: </strong>In 29% of TNBCs, PD-L1 was expressed. PD-L1 positivity was significantly associated with high tumor grade (P=0.007). PD-L1 did not, however, significantly associate with survival. CTLA-4 was expressed in 45% of TNBCs. CTLA-4 expression was significantly associated with lymph node metastasis (P=0.009), distant metastasis (P=0.001) and advanced TNM stage (P=0.001). In TNBC, multivariate analysis identified CTLA-4 expression as an independent prognostic predictor for both disease-free survival (P=0.002) and overall survival (P=0.003).</p><p><strong>Conclusion: </strong>The selection of patients for immunotherapy and checkpoint-blockade treatment may be guided by CTLA-4, an independent prognostic factor for the overall survival and disease-free survival of TNBC patients.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 1","pages":"319-326"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.1.319","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Programmed Death-Ligand 1 (PD-L1) and Cytotoxic T Lymphocyte -Associated Antigen-4 (CTLA-4) are presently considered as prognostic markers and therapeutic targets in numerous human malignancies. The goal of this study was to determine whether PD-L1 and CTLA-4 might be used to predict patients' survival in Triple Negative Breast Cancer (TNBC).
Methods: This retrospective cohort study analyzed 100 primary TNBC cases that had surgical resection at the Oncology Center of Mansoura University (OCMU), Faculty of Medicine, Egypt. Clinicopathological data and survival outcomes were collected, and immunohistochemistry (IHC) was performed for PD-L1 and CTLA-4 expression.
Result: In 29% of TNBCs, PD-L1 was expressed. PD-L1 positivity was significantly associated with high tumor grade (P=0.007). PD-L1 did not, however, significantly associate with survival. CTLA-4 was expressed in 45% of TNBCs. CTLA-4 expression was significantly associated with lymph node metastasis (P=0.009), distant metastasis (P=0.001) and advanced TNM stage (P=0.001). In TNBC, multivariate analysis identified CTLA-4 expression as an independent prognostic predictor for both disease-free survival (P=0.002) and overall survival (P=0.003).
Conclusion: The selection of patients for immunotherapy and checkpoint-blockade treatment may be guided by CTLA-4, an independent prognostic factor for the overall survival and disease-free survival of TNBC patients.
期刊介绍：
Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation.
The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally.
The APJCP publishes original research results under the following categories:
-Epidemiology, detection and screening.
-Cellular research and bio-markers.
-Identification of bio-targets and agents with novel mechanisms of action.
-Optimal clinical use of existing anti-cancer agents, including combination therapies.
-Radiation and surgery.
-Palliative care.
-Patient adherence, quality of life, satisfaction.
-Health economic evaluations.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
